当前位置:公众访问 >页面
简体中文 / English
1.Screening and Recruitment
1.1.Inclusion Criteria

Age

patients with coronary heart disease

Sign the informed consent

Risk stratification for patients with low or middle risk

1.2.Exclusion Criteria

Patients in one of the following condition are excluded

1.3.Basic Information of Subjects

Name

gender

people

Height

cm

weight

kg

abdomen circumference

cm

left ventricular ejection fraction(LVEF)

stents implanted

anamnesis

Body Mass Index

kg/m2

smoking history

blood cholesterol level in hospital

mmol/l

drink history

Bad mood performance

exercise habit

The drug

2.baseline index
2.1.Clinical Index

heart rate in anaerobic domain

次/分

heart rate in the peak oxygen uptake

次/分

blood pressure in Anaerobic domain

mm/Hg

blood pressure in the peak oxygen uptake

mm/Hg

the oxygen uptake in the rest

ml/kg/min

the oxygen uptake in anaerobic threshold

ml/kg/min

Peak oxygen uptake

ml/kg/min

target heart rate

次/分

Treadmill load

w

blood pressure in the rest

次/分

blood pressure in the rest

mm/Hg

2.3.Biomarkers in plasma

Phosphodiesterase 9A

ng/ml

Inflammatory factors

ng/ml

Immune-modulatory marker

ng/ml

left ventricular dysfunction marker

ng/ml

myeloperoxidase

ng/ml

adiponectin

ng/ml

extracellular-matrix remodeling markers

ng/ml

3.At the end of the treatment
3.1.Clinical Index after treatment

heart rate in anaerobic domain

次/分

heart rate in the peak oxygen uptake

次/分

blood pressure in the rest

mm/Hg

blood lipid level in Peak oxygen uptake period

mm/Hg

the oxygen uptake in the rest

ml/kg/min

the oxygen uptake in anaerobic threshold

ml/kg/min

Peak oxygen uptake

ml/kg/min

target heart rate

次/分

Treadmill load

w

heart rate in the rest

次/分

blood pressure in the rest

mm/Hg

3.2.Biomarkers in plasma after treatment

Phosphodiesterase 9A

ng/ml

Inflammatory factors

ng/ml

Immune-modulatory marker

ng/ml

left ventricular dysfunction marker

ng/ml

myeloperoxidase

ng/ml

adiponectin

ng/ml

extracellular-matrix remodeling markers

ng/ml

4.Follow-up after 3 months

Patients with follow-up of 3 months is discomfort or not

stick to exercise or not in the follow-up after 3 months